Neurocrine Biosciences, Inc. (NBIX) Company Profile & Statistics

Neurocrine Biosciences, Inc.
NBIX
(Nasdaq - US)
N/A
137.17
-1.80 (-1.29%)
in:usd•As of: Apr 25, 2024 14:04 UTC -4
Open
138.70
High
139.16
Low
136.12

About Neurocrine Biosciences, Inc.

CEO

Kevin C. Gorman

Headquarters

12780 el camino real

san diego, ca 92130, united states

Auditor

Ernst & Young LLP

Employees

1,400

Share Holders

Website

www.neurocrine.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.

Neurocrine Biosciences, Inc. Statistics

Valuation Measures

Market Capitalization ²	13.65B
Enterprise Value	13.57B
Enterprise Value/EBITDA (ttm)	53.29
Price to Earnings Ratio (ttm)	57.89
Price to Book (mrq)	6.17
Price to Sales (ttm)	7.39
Price to Cash (ytd)	54.32

Profitability

Gross Margin (ttm)	97.89%
Operating Margin (ttm)	13.23%
Profit Margin (ttm)	12.05%
Return on Equity (ttm)	12.85%
Return on Invested Capital (ttm)	11.79%
Return on Assets (ttm)	9.02%

Income Statement

Revenue (ttm)	1.89B
Revenue Per Share (ttm)	18.96
Gross Profit (ttm)	1.85B
EBITDA (ttm)³	254.60M
Net Income Avi to Common (ttm)	249.70M
Diluted EPS (ttm)	2.42

Share Statistics

Beta (5Y Monthly)	0.25
52-Week Change	33.99%
S&P500 52-Week Change	24.01%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	99.51M
Dividend Yield	0.00%
Float ⁴	95.13M
% Held by Insiders	4.40%
% Held by Institutions	92.59%

Balance Sheet

Total Cash (mrq)	1.03B
Total Cash Per Share (mrq)	10.37
Total Debt (mrq)	170.10M
Total Debt/Equity (mrq)	7.62%
Current Ratio (mrq)	2.45%
Quick Ratio (mrq)	2.40%
Book Value Per Share (mrq)	22.61

Cash Flow

Operating Cash Flow Per Share (ytd)	3.86
Free Cash Flow (ytd)	361.60M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Neurocrine Biosciences, Inc.

Trade With A Regulated Broker